RA, MS & Psoriasis: High Dose Vitamin D Therapy - video and summary

RA, MS & Psoriasis: High Dose Vitamin D Therapy Time Lines ( Coimbra Protocol )

Youtube 16 minutes - Feb 2026

Cure4Pain: summarized by Claude AI, June 2026

Summary:

  • [00:00–02:18] The "pharmaceutical cascade" critique: The video opens by arguing conventional treatment traps patients in a cycle where each drug depletes nutrients (metformin→B12/magnesium, PPIs→broad malabsorption, statins→CoQ10), creating new symptoms that prompt more prescriptions. A "typical" patient on 9 medications is presented as the failure mode of standard care.

  • [02:18–03:26] Proposed 7-stage autoimmune pathogenesis: Long-standing vitamin D3 deficiency → metabolic syndrome → triggering infections (EBV, bacterial, parasitic, fungal) → gut biofilms blocking D3 absorption → VDR dysfunction → Th17/Treg imbalance → tissue-specific damage. The claim is that MS, RA, psoriasis, lupus, and Type 1 diabetes share this root pathology with different target organs.

  • [04:02–05:09] Blood-work pattern interpretation: The presenter assigns specific meanings to CBC differentials (high eosinophils=parasites, high neutrophils=viral/EBV, high lymphocytes=fungal) alongside markers like fasting insulin >5, HbA1c, D3 <30 ng/mL, and elevated PTH as a signal of "D3 resistance." Note: these interpretive leaps are not standard clinical practice.

  • [05:35–07:19] Phase 1 loading protocol (0–4 months): Broad empiric antiparasitics/antifungals (ivermectin, albendazole, metronidazole, fluconazole) for 4–6 weeks to "break biofilms"; bile salts 200 mg + betaine HCl 600 mg to improve absorption; vitamin D3 60,000 IU 3–5×/week with cofactors (magnesium 400–800 mg, K2-MK7 100 mcg, B-complex, zinc, boron, selenium, chromium, omega-3, iodine); berberine 1800 mg for diabetics; immediate statin/PPI discontinuation.

  • [07:19–09:21] Phases 2–4 (de-escalation and maintenance): Phase 2 (4–12 mo): D3 reduced to 60,000 IU 2–3×/week, ionized calcium and PTH monitored as safety indicators. Phase 3 (12–24 mo): D3 60,000 IU 2×/week, most patients reportedly pharmaceutical-free. Phase 4 (lifetime): D3 60,000 IU 1×/week with cofactors 3×/week.

  • [09:21–11:35] Claimed condition-specific timelines: Psoriasis 2–8 months (80–95% clearance), RA ~18 months (95% pain reduction), MS ~18 months ("highly variable, requires perfect adherence"), Type 2 diabetes 6–12 months to drug-free if HbA1c falls below 5.7%, lupus/scleroderma 2+ years.

  • [11:35–12:43] Compliance as the main obstacle: The presenter states the hardest barrier isn't biology but adherence — patients quit when feeling better, experience a "healing crisis" in weeks 2–3, or stop labs. The clinic uses WhatsApp reminders and compliance tracking software.

  • [12:43–14:23] Cost comparison framing: Biologics positioned at $30,000–$72,000/year vs. the protocol at ~$720/year after year one (priced in Indian rupees, suggesting the clinic is based in India).

  • [14:23–15:53] Closing pitch: Reframes autoimmune disease as "reversible, not incurable," urges viewers to subscribe and comment with their condition and medication list.

Important caveats

  1. This is not the Coimbra Protocol despite the title. Dr. Cicero Coimbra's actual protocol uses individualized D3 dosing based on PTH suppression (often 1,000 IU/kg or higher), strict calcium restriction, and 2.5 L/day water intake — none of which are described here. The fixed 60,000 IU schedule, empiric antiparasitics, and biofilm framing are this clinic's additions.

  2. No citations, no published outcomes data, no RCT support is offered for the timeline claims. "Seven years, thousands of patients, 90% remission" is asserted without reference to peer-reviewed publication.

  3. Empiric ivermectin/albendazole/metronidazole/fluconazole "without identifying organisms" is contrary to antimicrobial stewardship and carries real hepatotoxicity, QT, and resistance risks.

  4. Stopping statins and PPIs "in 90% of cases" and the diagnostic leaps from CBC differential to specific infection classes are not supported by the literature.

  5. The economic-incentive framing ($720 vs $30k+) and "the system is failing you" rhetoric are classic engagement hooks — useful to note when evaluating whether this fits VitaminDWiki's evidence-tiering standard. If you pull from this for a page, it would likely sit in the "anecdotal clinical claim" tier with explicit "what this does NOT show" treatment.

Related in VitaminDWiki